Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05819515 · ClinicalTrials.gov registry record · NA
Treatment of Gingival Recession Defects Using Platelet-Rich Fibrin With an Allogenic Dermal Matrix
A NA study of Gingival Recession, sponsored by University of Michigan.
- Completed
- Registry status
- NA
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT05819515: Completed NA study of Gingival Recession, sponsored by University of Michigan.
NCT05819515 is a NA study of Gingival Recession that has completed, run by University of Michigan. The registered enrollment target is 36 participants, above the 30-participant average among 10 other Gingival Recession trials with a reported enrollment target (20% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05819515, a NA study of Gingival Recession, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The study aims to test the non-inferiority of an Allogenic Dermal Matrix with Platelet-Rich Fibrin for treatment of gingival recessions in comparison to the Connective Tissue Graft.
Primary Outcome
Measured as a percentage of the total baseline recession defect that coverage was obtained at.
Conditions Studied
Interventions
- PROCEDURE Tunneled coronally advanced flap
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2023-04-29 |
| Est. Completion | 2024-03-27 |
| Phase | NA |
What the finished NCT05819515 record still lists
NCT05819515 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, above the 30-participant average among 10 other Gingival Recession trials with a reported enrollment target (20% higher).
The record links to 1 condition, with Gingival Recession appearing as the primary indexed condition, and to 1 intervention - of which Tunneled coronally advanced flap is the first listed.
NCT05819515 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT05819515 about?
NCT05819515 is a clinical study titled "Treatment of Gingival Recession Defects Using Platelet-Rich Fibrin With an Allogenic Dermal Matrix". The study aims to test the non-inferiority of an Allogenic Dermal Matrix with Platelet-Rich Fibrin for treatment of gingival recessions in comparison to the Connective Tissue Graft.
What is the current status of trial NCT05819515?
This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2023-04-29. Estimated completion is 2024-03-27.
What conditions does trial NCT05819515 study?
This clinical trial studies the following conditions: Gingival Recession.
What interventions are being tested in trial NCT05819515?
The interventions under investigation include: Tunneled coronally advanced flap (PROCEDURE).
Who is sponsoring clinical trial NCT05819515?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05819515 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gingival Recession
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05819515's enrollment target sits among peer trials
36 4th of 10 higher than 7 of 10 other Gingival Recession trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gingival Recession trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gain of Keratinized Mucosa Around Teeth and Dental Implants Using a Combination of Strip Gingival Graft and Acellular Dermal Matrix
RECRUITING · NA
-
Patient-reported Outcomes of Donor Site Healing Using Different Palatal Protection Techniques
RECRUITING · NA
-
Changes of Soft Tissue Grafting: A Randomized Study
RECRUITING · NA
-
A Comparison of Side Access Mucosal Releasing Incision (SAMRI) and Sulcular Tunnel Access to Treat Gingival Recession.
ACTIVE NOT RECRUITING · NA
-
Thick vs. Thin Acellular Dermal Matrix (ADM)
COMPLETED · NA
-
Evaluation of Geistlich Fibro-Gide® + CAF in Comparison to CTG + CAF for the Treatment of Recession Defects at 6 Months
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI